JournalArta
Tuesday, November 17, 2026 · JakartaS&P 7,338.96 ▼1.05%USD/IDR 18,273 ▲0.12%
JournalArta
Global Edition
beyond headlines
Advertisement

Cochlear Share Price on Tuesday: Rises 1.15%, Up 9.4% in a Month

Technical analysis of Cochlear stock on November 17, 2026: price 152.56 AUD, trend uptrend, RSI 62.8, support 139.82, resistance 155.47.

By Alistair Sterling
November 17, 20264 min read
Cochlear Share Price on Tuesday: Rises 1.15%, Up 9.4% in a Month
Logo Cochlear — JournalArta illustration

Why Cochlear is in focus today

    Selected automatically from 9 ASX (Australia) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.

    Cochlear rose 1.15% to A$152.56 on the ASX on Tuesday, November 17, extending a one-month gain of 9.44% as its price held above both key moving averages. The advance is technically constructive, but modest five-day growth and thin trading volume temper the strength of the signal. The shares are up 0.10% over five days and sit 81% of the way through their 20-session range, close to the three-month high of A$155.72. That leaves room before the recent peak, but also means the stock is trading nearer resistance than support.
    Advertisement

    Trend & Price Action

    Cochlear’s A$152.56 price is above its 20-day simple moving average, or SMA, at A$146.71 and its 50-day average at A$139.64. The shorter-term average is also above the longer-term one, a structure consistent with an uptrend. No new moving-average crossover formed in the latest session, so the signal is an established trend rather than a fresh technical trigger. The 20-day average rose 3.43% over five days. That steepening suggests recent upward momentum has improved, even as the share price itself was nearly unchanged over the same period. The distinction matters: the moving average reflects the trend in prices over time, not a five-day share-price return. The price remains above rising averages, but is approaching resistance at A$155.47, the 20-session level, and the three-month high of A$155.72. The chart shows price, moving averages, Bollinger bands and support and resistance levels.
    Price action chart of Cochlear
    3-month price action chart of Cochlear: price, SMA20/50, Bollinger, support & resistance.
    Advertisement

    Oscillators & Momentum

    Momentum indicators are positive overall, though they do not all point to the same near-term pace. The RSI, a measure of recent gains versus losses, stands at 62.8, in neutral territory. That is consistent with an upward trend that has not yet reached the conventional overbought zone, although the research signal notes the RSI is rolling over from above 65. The stochastic oscillator, which compares the latest price with its recent range, is overbought at 81.0 for %K and 76.3 for %D. This does not by itself establish a reversal, but it signals that the share price has advanced toward the upper end of its recent trading range and could be vulnerable to a pause. MACD, a trend-and-momentum measure, remains positive: its reading of 4.225 is above the 3.884 signal line, with a positive 0.341 histogram. Positive MACD supports the trend, while the overbought stochastic argues for caution on immediate momentum. The chart below plots RSI, MACD and stochastic.
    Momentum chart of Cochlear
    Momentum chart of Cochlear: RSI(14), MACD, Stochastic.
    Advertisement

    Volatility, Volume & Key Levels

    Cochlear’s Bollinger band position is elevated but not at the upper boundary: %B is 76%, between the middle band at A$146.71 and the upper band at A$157.78. Band width is 15.1%, described as normal, so the data do not indicate an unusually tight squeeze or a sharp volatility expansion. ATR, a measure of typical price movement, is A$4.57, or 3.0% of the share price, indicating moderate volatility. Volume was 200,829 shares, about half the 20-session average of 397,319, which makes the latest rise a less convincing measure of broad market participation. OBV, a cumulative volume-based indicator, is rising; that offers a counterpoint, suggesting buying pressure has generally accumulated despite the subdued latest session. Support is A$139.82 and resistance is A$155.47. A move through resistance would put the three-month high of A$155.72 in focus; failure to hold the trend could bring the A$146.71 20-day average into view, with the 20-session support below it. Those levels describe conditional scenarios, not assured price moves.
    Advertisement

    Technical Verdict: BUY

    JournalArta Research assigns Cochlear a BUY verdict with a score of +76 on its −100 to +100 scale. The strongest supporting signals are the price above its 50-day average, the 20-day average above the 50-day, and the rising OBV confirming the broader uptrend. Positive MACD adds support. The overbought stochastic and thin latest volume are the main near-term risks. The verdict is invalidated if the price falls below A$144.77. - Ideal entry range: A$149.13–A$152.56 - Exit targets: A$164.24 (target 1) and A$175.93 (target 2) - Stop-loss protection: A$144.77 - Valid until: December 15, 2026 In plain English, the trend indicators favour further strength, but near-term momentum and light volume leave room for a pullback.
    IndicatorReading
    Last priceA$152.56
    Daily / five-day / one-month change+1.15% / +0.10% / +9.44%
    SMA20 / SMA50A$146.71 / A$139.64
    RSI / Stochastic62.8 / 81.0 (%K), 76.3 (%D)
    MACD / signal / histogram4.225 / 3.884 / 0.341
    20-session support / resistanceA$139.82 / A$155.47
    Three-month high / lowA$155.72 / A$124.33
    Advertisement

    Summary Data Cochlear

    Last price152.56 AUD
    Change 1 day / 5 days / 1 month1.15% / 0.10% / 9.44%
    Trend / MA-crossuptrend / none
    SMA20 / SMA50146.71 / 139.64
    RSI (14) / Stochastic %K62.8 / 81.0
    Bollinger %B / ATR76% / 4.57
    Support / Resistance 20 days139.82 / 155.47
    Data as of17 November 2026 12:10 WIB
    JournalArta research verdict (score)Buy (+76)
    Entry zone149.13 – 152.56
    Target 1 / 2164.24 / 175.93
    Stop loss144.77
    Reward/risk1.5 / 3.0

    Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.

    Advertisement
    Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
    Advertisement
    Most Read
    1. 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage
    2. 2DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI
    3. 3Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds
    4. 4NASA’s Curiosity Rover Burst Open a Rock and Found Pure Sulfur
    5. 5Stock Market Today: Dow Futures Slip as Nasdaq Futures Climb Before Earnings
    Advertisement
    Don't Miss

    Latest News

    All stories →
    1. Markets · StocksWoolworths Share Price on Tuesday: Falls 0.36%, Up 1% in a MonthNov 17
    2. Lifestyle · EntertainmentJames Bond Sucks Makes Robert Pattinson’s Casting a Vampire JokeNov 17
    3. Lifestyle · Food & HealthMayo Clinic Study Links Blood Biomarker to Future Cognitive RiskNov 17
    4. Sport · More SportsTiger Woods Returns to Competition at Hero World ChallengeNov 17
    5. Advertisement
    6. Sport · More SportsWoods Backs PGA Tour Overhaul Set to Begin in 2028, Rolapp Says No LIV Return PlansNov 17
    7. World · EuropeLloyd Scott, Charity Fundraiser Who Raised More Than £5M, Dies at 65Nov 17
    8. Lifestyle · EntertainmentBrad Pitt Pitches Himself as a Villain in Robert Pattinson’s James Bond FilmNov 17
    9. Lifestyle · EntertainmentSarah’s Channel Turns Beauty Blogging Into Post-Apocalyptic HorrorNov 17